NCT06522594View on ClinicalTrials.gov

REMAP ECMO - Beta Receptor Modulation Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

December 3, 2025

Conditions
Heart FailureCardiogenic Shock
Interventions
DRUG

Esmolol

A vey cardioselective, short-acting betablocker, with an ultra-short half life time.

Trial Locations (1)

3015GD

RECRUITING

Erasmus Medical Center, Rotterdam

Sponsors
All Listed Sponsors
lead

Erasmus Medical Center

OTHER

NCT06522594 - REMAP ECMO - Beta Receptor Modulation Trial | Biotech Hunter | Biotech Hunter